Aurobindo Pharma’s subsidiary, TheraNym Biologics, is expanding its partnership with MSD (Merck Sharp & Dohme Singapore) by constructing a new $150–$175 million greenfield facility (Unit 2). This 60,000-litre mammalian bioreactor plant builds upon a May 2024 agreement to significantly boost Aurobindo’s biologics manufacturing capacity for global markets.

The facility will include advanced downstream purification infrastructure to manufacture biologic drug substances for both domestic and international markets. 

As part of the expansion, TheraNym will invest approximately $150 million to $175 million in the new unit. The company said it will build the facility, manufacture the products, and supply them to MSD under the arrangement, strengthening Aurobindo’s biologics contract manufacturing footprint. 

The latest move deepens Aurobindo Pharma’s strategic push into biologics manufacturing and reinforces its long-term CMO relationship with MSD, as demand for large-scale mammalian cell culture capacity continues to rise globally.